Introduction
============

Renal cancer incidence is increasing^[@bib1]^ and Central/Eastern Europe has the highest rates worldwide.^[@bib2]^ Most (∼90%) adult renal cancers are renal cell carcinomas (RCC), most of which are clear cell RCC (ccRCC).^[@bib3]^ ccRCC can be further classified by genetic features, most notably by the presence/absence of Von Hippel--Lindau (*VHL*) gene inactivation, which occurs through three mechanisms: sequence alteration affecting the transcript or protein, transcriptional silencing because of promoter CpG hypermethylation and loss of heterozygosity/copy number of the 3p25-26 locus.^[@bib4]^

The VHL protein is involved in tissue-specific responses to oxygen concentration delivery.^[@bib5],\ [@bib6]^ *VHL* alteration through sequence changes and/or promoter hypermethylation, leading to transcriptional silencing, prevents formation of a protein complex required for hypoxia-inducible factor (HIF) degradation, resulting in excess HIF protein and a gene expression pattern facilitating adaption to oxygen deprivation, delivery and angiogenesis. *VHL* inactivation subtypes have been associated with improved prognosis and a favorable treatment response in some but not all studies.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ In contrast, *VHL* wild-type cases may occur through mechanisms independent of *VHL* inactivation. Generally, *VHL* inactivation is considered an early event in ccRCC but other unidentified alterations may accompany *VHL* alteration at diagnosis.

ccRCC subgroups have demonstrated different frequencies and patterns of *VHL* inactivation associated with known risk factors, which include obesity, hypertension, smoking, certain occupational exposures and a positive family history of kidney cancer.^[@bib12],\ [@bib13]^ High-intake of fruits and vegetables may reduce risk.^[@bib1]^

In this study we used array comparative genomic hybridization to evaluate chromosomal alterations among incident ccRCC cases enrolled in a large case--control study of renal cancer. Risk factors, tumor histopathological features and *VHL* gene inactivation were evaluated for association with the frequency and type of copy number alterations observed.^[@bib14],\ [@bib15],\ [@bib16]^

Results
=======

Cases with tumor biopsies (*N*=412) were more likely to be residents from the Czech Republic, have a family cancer history and have a higher education level compared with those without biopsies (*N*=348) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Other factors did not differ.

Fraction of genome altered (FGA)
--------------------------------

Males had a higher FGA compared with females (*P*=0.002) ([Figure 1](#fig1){ref-type="fig"}). Stage and grade at diagnosis were associated with increasing fraction of the genome lost (FGL), fraction of genome gained (FGG) and total FGA (*P*\<0.0001). Ever smokers had elevated FGG (*P*=0.05) and FGA (*P*=0.05) compared with never smokers, but trends with current smoking status were not observed (*P*=0.62). Individuals without a first degree relative with cancer had a higher FGA compared with those who did (27.9% vs 22.8% *P*=0.02). A lower FGA was observed in cases with *VHL* promoter hypermethylation (20.8%, *P*=0.03) and sequence alteration (25.9%, *P*=0.11), compared with wild-type cases (30.5%-referent). FGA was not associated with other factors.

Chromosomal alterations
-----------------------

The exact number and percent of all chromosome p and q arm gains and losses in all ccRCC cases in this study are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Chromosome arms altered in greater than 25% of cases, and those of previous interest were included in multivariate models ([Table 1](#tbl1){ref-type="table"}). The strongest association was observed between 3p loss and *VHL* gene inactivation (*P*\<0.0001). 3p loss was less frequent among *VHL* wild-type compared with inactivated cases (70.2% vs 95.3%, respectively). Therefore, 29.8% of *VHL* wild-type and 4.7% of inactivated cases had 3p present. No other factors with the exception of *VHL* inactivation were associated with 3p loss. Stage was strongly associated with 9p, 9q and 13q (*P*\<0.0001), and to a lesser extent 1p, 10q and 14q losses. Stage was associated with 12p and 20q gains (*P*=0.001). Grade was strongly associated with 8p and 14q (*P*=\<0.0001) and also 1p, 4q, 6q, 9p, 9q and 13q losses. Gains associated with grade were observed at 5p, 7p, 7q and 12q.

After adjustment, male cases had more losses of 3q, 9p, 9q, 13q, 14q and gains of 5p, 7q, 12p, 12q, 20q. Most of these alterations were associated with stage and/or grade. Patients 65 years or older had more 4q, 9p and 9q losses compared with younger patients diagnosed before age 50. Individuals that reported a family cancer history had fewer 7q gains and 8p losses, explaining the lower FGA observed. In contrast, there were no chromosome arm alterations associated with smoking status. Interestingly, 5q gain was frequently observed although it was not associated with any of the patient/clinical characteristics or risk factors evaluated. Closer examination revealed that gains occurred distally, specifically at two regions (that is, 5q34--35 (55--58%), 5q31--32 (52--54%) and 5q21--23 (34--49%) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"})).

Loci
----

Differences in copy number alteration prevalence at specific loci and risk factors were compared using a moderated *t*-statistic or F statistic with pooled variance, controlling the false discovery rate (FDR). High frequency clonal alterations were sorted initially by FDR-adjusted *P*-values. Subsequently, significant loci were re-analyzed in adjusted models ([Table 2](#tbl2){ref-type="table"}). Grade was associated with loss of large regions on 4q, 9q, 13q, 14q, 18q and gains on 1q, 7p. Stage was associated with large losses on 9p, 9q, 13q, 14q, 17q, 18q and gains on 3q and 7q. Both stage and grade were associated with loss of 1p36; 4q11-12,26; 9p21-22; 9q21-21.3; 14q13-14, 21, 24, 31-32; 18p11.2-12, 18q11-12, 21.3-23, tel; and gains on 3q22-23; 17q24-25; and 20q13. Both stage and grade were associated with losses on 14q23.2, a region harboring the *HIF1A* gene, and 14q13.2 harboring the *PHD1--EGLN3* gene. We examined HIF1A protein expression in tumor tissue microarrays using immunohistochemistry, in relation to 14q and regional (clonal) loss across the *HIF1A* region (14q23). Although univariate analyses suggested a decrease in expression with 14q and 14q23 loss, neither factor was associated with HIF1A expression after adjustment for stage and grade. Stage and particularly grade remained strongly associated with HIF1A expression, independent of 14q loss (data not shown).

Male cases exhibited losses on 6p22, 6p24--25, large regions of 9q and gains at 1q43-44, 12p12.3, 12q12.4, 24-tel, compared with females ([Table 3](#tbl3){ref-type="table"}). These alterations were also associated with stage and grade. Among cases reporting a positive family cancer history, fewer cases demonstrated losses at 4q21-23 (11% vs 24%, *P*=0.002) and gains at 20q13.2 (13% vs 26%, *P*=0.002). Former and current smokers exhibited more loss at 3q12 (24% vs 40%, *P*=0.04) and gain at 16p11.2-13 (22% vs 11%, *P*=0.003). Interestingly, a significant positive trend was observed with current smoking status and gain at 16p11.2-13.2 (*P*-trend=0.003). Lastly, copy number alteration of specific clones and *VHL* inactivation status were evaluated. The lowest FDR-adjusted *P*-values that remained significant in multivariate analyses were losses observed at clones RP11-245E5 (3p24; *P*\<0.0001) and RP11-180G14 (3p14.3; *P*\<0.0001). RP11-180G14 (3p14.3) is located just distal to CTD-2175D15 (3p14.2), a clone harboring the *FHIT* locus ([Figure 2](#fig2){ref-type="fig"}).

To follow-up upon these observations, the prevalence of all 3p losses was compared between groups stratified by *VHL* inactivation characteristics. Clonal alteration prevalence among wild-type cases were compared separately to cases demonstrating inactivated through *VHL* promoter hypermethylation or sequence alteration. Loss of these 3p clones was significantly greater among cases with *VHL* sequence alterations compared with wild-type cases. Losses were significantly more prevalent at the 3p telomere (93% vs 59%, *P*\<0.00001), and clone CTB110-J24 (3p25-26;*VHL)* (95% vs 62%, *P*\<0.00001) (Region A-[Figure 2](#fig2){ref-type="fig"}), and at 3p14.2 (*FHIT)* (92% vs 75%, *P*=0.001) but not at regions proximal to the centromere. Loss of 3p loci among *VHL* hypermethylated cases was similar in prevalence to cases with sequence alterations but significantly higher compared with wild-type cases at the 3p telomere (83%, *P*=0.03) and the *VHL* locus (91%, *P*=0.0006) (Region A-[Figure 2](#fig2){ref-type="fig"}), but not significantly different to wild-type cases at loci centromeric to clone RP11-180G14 (3p14.3; Region B-[Figure 2](#fig2){ref-type="fig"}). Loss among hypermethylated cases was significantly less prevalent than among cases with sequence alterations at 3p14.2 (84%, *P*=0.04) and regions proximal to the centromere (50%, *P*=0.0002). These findings demonstrate differences in 3p loci loss between *VHL* inactivation subgroups, in particular clones surrounding the fragile *FHIT* locus. Lastly, *VHL* wild-type cases were distinguished by having more gains at clone LLNL-255K9 (20q11-12) compared with inactivated cases (33% vs 20%, *P*=0.03) ([Table 3](#tbl3){ref-type="table"}), a clone that was also more prevalent in cases with higher stage.

Amplifications
--------------

High-level amplifications were observed at 154 clones among 24 cases (1--28 amplifications/case). The most frequent amplifications were located at clones RP11-28l11 (11p15.2-15.4; *N*=6), RP11-10M23, RP11-91H14, RP11-121G20 (6p21.1-21.2; *N*=5) and CTB-136O14 (12q14; *N*=3). Two cases (one *VHL* wild-type with 3p present; one *VHL* inactivated with 3p loss) demonstrated 2q/6p co-amplifications. The 2q overlapping region (∼179.4--199.8 Mb) covers ∼100 genes; the 6p overlapping region (∼39.1--45.7 Mb) included the *VEGF* (vascular endothelial growth factor) gene.

Discussion
==========

Previous studies have utilized copy number profiling to classify histologically categorized RCC cases into molecularly defined subtypes ([Table 4](#tbl4){ref-type="table"}).^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ Consistent with previous studies, the most common alterations were loss of 3p, 14q and gain of 5q.^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ Two previous comparative genomic hybridization studies examined associations between RCC copy number variation with stage and grade.^[@bib18],\ [@bib20]^ One study (51 cases) reported two clusters defined solely by the alteration subtypes observed.^[@bib18]^ In both clusters, 3p loss and 5q gain were frequently observed, however, one cluster, defined by losses on 1p, 4, 9, 13q and 14q, had a higher stage and grade, increased vascular involvement and lower overall survival that were independent of stage and grade.^[@bib18]^ Another study (51 cases) reported a difference in genomic copy number and expression profiles between cases with/without biallelic *VHL* loss.^[@bib18]^ A study of 80 cases observed significant associations with stage and loss of 14q and 18p.^[@bib20]^ In the current study, both stage and grade were associated with losses on 14q harboring *HIF1A* (14q23.2) and *PHD1-EGLN* genes (14q13.2). Recently, genetic and functional studies reported that HIF1A is a target of 14q loss and that HIF1A activity is diminished in 14q deleted RCC cases.^[@bib21]^ Loss of these loci being associated with 14q loss was not corroborated in the current study, perhaps because of differences in type of study design and laboratory methodologies. In the current study, loss of specific loci spanning 14q23 was associated with stage and grade, which is consistent with the poor prognosis reported in 14q deleted cases.^[@bib18]^

This is the first study to evaluate 3p loci loss among large numbers of cases that were also defined by *VHL* status. In multivariate analyses, only *VHL* gene alteration was associated with 3p loss. Cases with *VHL* promoter hypermethylation were similar to those with sequence alterations at loci distal to the *FHIT* locus, and to wild-type cases at loci centromeric to *FHIT*. This observation suggests that in hypermethylated cases, the *FHIT* breakpoint could be critical in terms of somatic copy number loss of the chromosome segment distal to 3p14.2. In contrast, the *FHIT* fragile site was not a significant breakpoint in *VHL* wild-type or cases with sequence alterations. The *FHIT* region spans the most common fragile site of the human genome (the FRA3B fragile site) encompassing the previously observed familial kidney cancer breakpoint (t(3;8) p14.2;q24) and a viral integration site.^[@bib23],\ [@bib24],\ [@bib25]^ Hemizygous, interstitial or terminal 3p deletions involving the *FHIT* gene and reduced protein expression have been observed in over 90% of ccRCC cases, similar to that observed in the current study (89%).

In addition to heterogeneity across 3p by *VHL* inactivation subgroups, we found that wild-type tumors had more alterations compared with those with *VHL* inactivation through promoter hypermethylation; corroborating a previous report that wild-type cases may be less genetically stable than hypermethylated cases, and possibly those with sequence alterations.^[@bib20]^ The higher genomic instability among wild-type cases suggests a greater potential for progression, as copy number alterations have been associated with tumor stage, grade and worse prognosis.

Analyses of patient characteristics revealed that male cases had more alterations compared with females. The most prevalent copy number alterations in males occurred independently of stage and grade. This could indicate that incident male ccRCC tumors could be more aggressive compared with female cases, regardless of stage or grade at diagnosis. Male patients might also benefit from more aggressive treatment, follow-up and their genetic alterations could provide clues for targeted therapies. Several target genes on chromosome 9 include *CDKN2A* and *CDKN2B*.^[@bib19],\ [@bib20]^ Other risk factors examined did not explain the sex differences observed. Additional characteristics associated with tumor heterogeneity included having a first degree relative with cancer in which fewer copy number alterations were observed compared with those without cancer history. Smoking was associated with higher FGA. Ever smoking was associated with copy number loss of 3q12-14, gain of 16p11.2-13.2 for which a significant, positive trend with current smoking status was found.

As previously reported, 5q gain was highly prevalent and was not associated with of stage, grade, *VHL* inactivation suggesting that these loci may provide clues to the location of additional genes that are also altered in the early stages of ccRCC development. Two recent studies that employed SNP arrays^[@bib19],\ [@bib20]^ also observed gains at the distal end of 5q. Expression analysis revealed overexpression of 12 of 22 5q genes in tumor compared with normal cortex, including: *GNB2L1*, *MGAT1*, *RUFY1*, *RNF130*, *MAPK9*, *CANX*, *CNOT6*, *SQSTM1*, *LTC4S*, *TBC1D9B*, *HNRPH1*, and *FLT4*.^[@bib19]^ A second study reported focal amplification of 5q35.3 containing the *SQSTM1* gene that is overexpressed in other cancers.^[@bib20]^ The weak correlation between 5q gain and 3p loss across studies suggests that new targets, perhaps functioning through VHL-HIF independent mechanisms, could be identified on 5q.

This study included a large series of histologically-confirmed ccRCC cases with detailed risk factor and patient/clinical information. Our two-step analytical approach, entailing FDR adjustment and subsequent multivariate analyses of significant loci, reduced possible false-positive reporting. Weaknesses included a low sample size for interaction analyses and potential selection bias from exclusion of almost 50% of cases. We also used a relatively low resolution array compared with some studies. However, the current study utilized available high-quality information on each patient and RCC risk factors to an extent not previously evaluated in earlier studies. Results from reports that employed higher resolution techniques will complement our study findings and enable identification of smaller target regions/genes for follow-up.

In summary, we identified novel associations between patient/clinical characteristics and copy number alterations in a well-defined ccRCC case-series. Considerable heterogeneity spanning the *FHIT* gene locus suggests that this fragile site could be critical in terms of chromosomal loss of regions distal to 3p14.2 in cases with *VHL* promoter hypermethylation. Our findings also suggest that male tumors may be less genetically stable compared with those in female cases, and may benefit from more aggressive follow-up. Lastly, this study provides evidence that loci on 5q may provide clues to RCC carcinogenesis that could be distinct to the VHL-HIF pathway.

Materials and methods
=====================

Study population
----------------

Incident cases (ICD-02 code C.64) were participants in a case--control study of RCC conducted in seven centers in four Central and Eastern European countries (Moscow, Russia; Bucharest, Romania; Lodz, Poland; and Prague, Olomouc, Ceske-Budejovice, and Brno, Czech Republic).^[@bib14],\ [@bib15]^ Diagnostic slides were re-reviewed by an expert renal cancer pathologist for standardized classification (MM). Of 1097 cases, 763 were ccRCC, and frozen biopsies were available from 412 (54%) cases. Protocols were approved by ethics committees and institutional review boards of participating centers, the International Agency for Research on Cancer and the US National Cancer Institute. All patients and physicians provided written informed consent. Patients were asked about lifestyle habits, height/weight one year before diagnosis, personal/family medical history and diet.^[@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^

Array comparative genomic hybridization
---------------------------------------

Areas of frozen biopsies containing ⩾70% tumor cells were macrodissected and non-tumor tissue was removed.^[@bib13]^ A standard protocol (<http://cc.ucsf.edu/people/waldman/Protocols>) was used to extract DNA. Arrays included 2464 BACs at approximately Mb intervals along the genome, printed in triplicate.^[@bib22],\ [@bib26]^ DNA samples (500 ng) were labeled as described previously.^[@bib27]^

VHL
---

Inactivating alterations in exons 1--3 of the *VHL* gene and promoter hypermethylation were assessed as described previously.^[@bib13]^ Wild-type tumors included those without sequence alterations affecting the protein coding region, splice junctions or promoter hypermethylation.

Data processing
---------------

Data were processed using SPROC to filter data points with low DAPI intensity, reference to DAPI signal intensity and correlation between Cy3 and Cy5 within spots. Ratios that were derived from a single clone or those with a triplicate log2 SD \>0.2 were considered missing. Samples were hybridized on two versions of human array (3.1, 3.2). Clone data were combined sharing data from both arrays. Post-processing, 2111 clones remained. Data were mapped to the human DNA sequence May 2004 freeze.

Data were segmented using circular binary segmentation,^[@bib28]^ implemented in the DNAcopy package from Bioconductor^[@bib29]^ to translate intensity measurements into equal copy number regions. Median absolute deviation, scaled by the factor 1.4826 of the difference between the observed (log2 ratio) and segment values of autosomal clones, were used to estimate sample-specific experimental variation. Clone status outcome assignment (gain/loss/normal) was conducted, applying the merge levels procedure to segment values.^[@bib30]^ To identify single technical or biological outliers (that is, high-level amplifications), their presence was allowed within each segment. Outlier clones included those for with an observed value at least four sample-specific median absolute deviation from the segment. High-level amplifications included narrow and single outliers with high copy numbers, as described previously.^[@bib31]^

To quantify the total amount of genome altered, each clone was assigned a genomic distance equal to the sum of one half the distance between its center and that of neighboring clones or to the chromosome end for probes with one neighbor.^[@bib31]^ FGA was defined as the proportion of the distance of the autosomal clone regions altered to that of the entire genome. FGG or FGL, considered only distances that were gained or lost.

Clone-wise association tests between copy number alterations and clinical variables were based on the segment values with observed values for outlier clones. Moderated *t*-tests for dichotomous variables and moderated F-statistics^[@bib32]^ were used for more than two groups. *P*-values were adjusted for multiple testing by controlling the FDR.^[@bib32],\ [@bib33]^ Wilcoxon\'s rank-sum tests were performed to evaluate differential associations of summary genomic events (that is, FGA, FGG, FGL, amplifications and specific alterations) with dichotomous variables. Kruskal--Wallis rank-sum tests were used for events having more than two groups. Statistical analyses of autosomes were performed using R/Bioconductor.^[@bib29],\ [@bib34]^ *P*-values \<0.05 were considered significant.^[@bib33]^

Copy number alterations
-----------------------

The prevalence of ccRCC cases with/without frozen biopsies were compared by patient characteristics using *χ*^2^ and Fisher\'s Exact tests. Alterations of chromosome arms were coded as '0\' (no alterations) and '1\' (dominant change), defined as gain or loss in \>25% of cases. Also included were those previously reported as important alterations in renal cancer. To compare cases with/without p or q arm alterations, cases with gains/losses were considered as dependent variables in stepwise logistic regression models with patient/clinical characteristics, lifestyle and occupational exposure variables. Criteria for inclusion into multivariate models was a *P*-value \<0.20. Study design matching variables (country, sex, age) were included in all models. All variables were fitted in logistic models to obtain odds ratios (OR) and 95% confidence intervals (95% CI) as risk estimates of each alteration. Individual clone copy number differences between groups were initially tested using a moderated *t*-statistic or F-statistic with pooled variance, adjusted for multiple comparisons controlling the FDR.^[@bib32]^ Clones identified through the first screen, observed in \>20% of cases, were included in multivariate analyses conducted using SAS 9.1.3 (SAS Institute Inc.) and STATA 10.0 software. Clone-wise tests were conducted in R,^[@bib34]^ all were two-sided.
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![Fraction (%) of the FGL, FGG and FGA among ccRCC case subgroups. *P*-values between subgroups were as follows: males vs females (*P*=0.002), age (\<50, vs ⩾50 years, *P*=0.06), any family history of cancer (*P*=0.02), stage (*P*\<0.00001), grade (*P*\<0.0001), ever vs never smoking (*P*=0.05), *VHL* wild-type cases vs those with *VHL* promoter hypermethylation (*P*=0.03), *VHL* wild-type cases vs those with *VHL* sequence alterations (*P*=0.17). REF, referent group.](oncsis201214f1){#fig1}

![Frequency of copy number loss of 3p clones among ccRCC cases grouped by absence (wild-type) or presence of *VHL* gene inactivation (through sequence alteration or promoter hypermethylation). Region A (telomere to RP11-180G14): the frequency of copy number loss of individual 3p clones differed significantly between *VHL* wild-type and inactivated cases that occurred through both sequence alteration (*P*\<0.00001) and promoter hypermethylation (*P*=0.03--0.001). Region B (from RP11-180G14to RP11-154H23): the frequency of clonal copy number loss differed significantly between wild-type cases and those with sequence alterations (*P*=0.003--\<0.00001), but was no longer observed with hypermethylated cases (*P*=0.08--0.59).](oncsis201214f2){#fig2}

###### Regression analysis of selected chromosomal arm alterations patient/clinical factors

  *Chromosome arm*   *Risk factors*                                 *Odds ratio (95% confidence intervals)*   P*-value*
  ------------------ ---------------------------------------------- ----------------------------------------- -----------
  1p−                Grade: I, II (REF) vs III, IV                  2.4 (1.3--4.2)                            0.003
                     Stage: T1 (REF), T2, T3-4                      1.6 (0.7--3.4); 3.7 (1.6--8.5)            0.001
  3p−                ***VHL*** gene inactivation: no (REF) vs yes   1250 (476--3125)                          \<0.0001
  3q−                BMI: \<25 (REF), 25--30, 30+                   2.5 (1.4--4.6); 1.9 (1.0--3.7)            0.01
                     Sex: female (REF) vs male                      2.4 (1.5--4.2)                            0.0004
  4q−                Grade: I, II (REF), vs III, IV                 2.3 (1.4--3.6)                            0.001
                     Age: \<50 (REF), 50--60, 60+                   1.6 (0.8--2.9); 3.0 (1.5--5.7)            0.001
  5p+                Grade: I, II (REF), vs III, IV                 1.6 (1.2--3.0)                            0.02
  6q−                Grade: I, II (REF), vs III, IV                 2.1 (1.3--3.3)                            0.004
  7p+                Grade: I, II (REF), vs III, IV                 2.1 (1.3--3.4)                            0.003
  7q+                Family history cancer: no (REF) vs yes         0.6 (0.4--0.9)                            0.02
                     Grade: I, II (REF), vs III, IV                 2.1 (1.3--3.3)                            0.004
  8p−                Grade: I, II (REF), vs III, IV                 3.0 (1.8--5.0)                            \<0.0001
                     Family history cancer: no (REF) vs yes         0.6 (0.4--0.9)                            0.01
  9p−                Grade: I, II (REF), vs III, IV                 2.2 (1.3--3.7)                            0.003
                     Stage T1 (REF), T2, T3-4                       3.3 (1.5--7.4); 6.3 (2.6--14.8)           \<0.0001
                     Age: \<50 (REF), 50--60, 60+                   1.9 (0.9--3.7); 3.1 (1.5--6.3)            0.006
                     Sex: female (REF) vs male                      2.0 (1.2--3.1)                            0.007
  9q−                Grade: I, II (REF), vs III, IV                 2.5 (1.4--4.2)                            0.001
                     Stage T1 (REF), T2, T3-4                       3.9 (1.6--9.2); 7.5 (3.0--18.6)           \<0.0001
                     Age: \<50 (REF), 50--60, 60+                   1.6 (0.8--3.2); 2.9 (1.4--5.9)            0.007
                     Sex: female (REF) vs male                      2.4 (1.5--4.0)                            0.0006
  12p+               Stage T1 (REF), T2, T3-4                       2.8 (1.2--6.6); 5.0 (2.1--12.2)           0.001
                     Sex: female (REF) vs male                      2.1 (1.3--3.7)                            0.005
  12q+               Stage T1 (REF), T2, T3-4                       1.2 (0.9--5.2); 4.8 (2.0--11.9)           0.001
                     Grade: I, II (REF), vs III, IV                 2.2 (1.8--4.0)                            0.01
                     Sex: female (REF) vs male                      2.3 (1.2--4.4)                            0.01
  13q−               Stage T1 (REF), T2, T3-4                       4.4 (1.3--15.1); 13.3(3.8--46.6)          \<0.0001
                     Grade: I, II (REF), vs III, IV                 3.2 (1.9--5.6)                            \<0.0001
  14q−               Organic solvents: no (REF) vs yes              1.9 (1.1--3.2)                            0.03
                     Sex: female (REF) vs male                      1.9 (1.1--3.1)                            0.03
                     Stage T1 (REF), T2, T3-4                       1.5 (0.8--2.9); 3.1 (1.5--6.7)            0.006
                     Grade: I, II (REF), vs III, IV                 4.4 (2.34--8.2)                           \<0.0001
  20q+               Stage T1 (REF), T2, T3-4                       1.3 (0.7--2.8); 3.1 (1.5--6.5)            0.001

Abbreviations: BMI, body mass index; VHL, Von Hippel--Lindau gene.

Adjusted for Center, age, sex, stage, grade and *VHL* gene inactivation.

###### Regional clone and copy number alterations and ccRCC tumor stage and grade

  *Chromosome arm*   *Clone with highest signal*   *Regions altered*          *Start (Mb)*     *End*     P*-value*[a](#t2-fn1){ref-type="fn"}    *Grade I, II (*%*) *vs* III, IV (*%)  *OR*[b](#t2-fn2){ref-type="fn"}    *95% CI*^b^   P*-value adj*^b^
  ------------------ ----------------------------- ------------------------- -------------- ------------ -------------------------------------- -------------------------------------- --------------------------------- -------------- ------------------
  *Grade*                                                                                                                                                                                                                               
  1p−                RP11-60J11 (1p36.2)           1p36                         7041.726     7 232 439   0.0041                                                 14/33                  2.94                               (1.66--5.21)  0.00001
  1q+                RP11-104A2 (1q32-41)          1q25, 31-41, 45            206 402.345     2.07E+08   1.58E-05                                                9/31                  4.42                               (2.34--8.36)  0.00001
  3q+                RP11-219P10                   3q22-23                    137 606.200     1.38E+10   0.0037                                                 12/25                  1.96                               (1.07--3.61)  0.03
  4p−                RP11-176I4 (4p15.1)           4p14-16                     33 086.961    33 087 410  5.85E-05                                               14/33                  3.10                               (1.73--5.57)  0.0001
  4q−                RP11-6K22 (4q 26-27)          4q11-13, 24,26-31,34,35    120 282.900     1.20E+08   7.79E-06                                               13/32                  3.43                               (1.88--6.26)  0.0001
  6q−                RP-2202A14 (6q14)             6q14                        79 297.260    79 474 213  0.0034                                                 19/37                  2.09                               (1.22--3.56)  0.007
  7p+                RP11-161C7 (7p22.3)           7p13-14,21-22.3              6215.911     6 396 692   0.0002                                                  2543                  2.27                               (1.36--3.79)  0.002
  7q+                RP11-10D8 (7q22.1)            7q22.1-.3                   98 067.790    98 216 726  3.78E-05                                               28/46                  2.17                               (1.31--3.60)  0.003
  8p−                RP11-182G2 (8p22)             8p22-23                      4457.862     4 614 130   3.33E-06                                               30/53                  2.59                               (1.56--4.27)  0.0001
  9p−                RP11-85J5 (9p21.3)            9p21-22                     24 524.208    24 524 427  1.97E-05                                               26/49                  2.32                               (1.38--3.92)  0.002
  9q−                RP11-106O17 (9q22.3)          9q21-33                     94 882.444    94 882 881  8.72E-06                                               25/47                  2.19                               (1.30--3.68)  0.003
  11q−               RP11-42L18 (11q22.3-23)       11q22-23                   107 422.086     1.08E+08   2.32E-05                                                8/25                  3.81                               (1.93--7.53)  0.0001
  12q+               RP11-89J2 (12q24.32)          12q13-14, 24.32            124 666.600     1.25E+08   0.0005                                                 17/29                  1.81                               (1.26--3.68)  0.04
  13q−               RP11-11C5 (13q21.3)           13q12-14.3, 21-tel          72 013.886    72 183 774  2.34E-06                                               10/41                  5.36                               (2.94--9.77)  0.00001
  14q−               RP11-26M6 (14q13)             14q12-14, 21.3-32.2         34 404.822    34 591 592  2.34E-06                                               34/67                  3.18                               (1.91--5.28)  0.00001
  17q+               RP11-84E24 (17q24-25)         17q24-25, tel               67 512.626    67 693 011  3.78E-05                                                5/22                  4.50                               (2.16--9.39)  0.00001
  18p−               CTD-2048F17(18p12)            18p11.21-11.32,12            8396.160     8 396 803   3.51E-06                                               14/38                  3.24                               (1.84--5.69)  0.00001
  18q−               RP11-60P1 (18q21.3)           18q11-12, 21.3-23, tel      59 072.800    59 251 211  3.44E-06                                               16/44                  3.80                               (2.20--6.55)  0.00001
  20q+               CTD2238P18 (20q12)            20q12,13                    45 712.070    45 864 616  0.0001                                                 17/37                  2.28                               (1.32--3.94)  0.003

  *Chromosome arm*   *Clone with highest signal*   *Regions altered*             *Start (Mb)*      *End*     P*-value*[a](#t2-fn1){ref-type="fn"}    *Stage I, II (%)*vs* III, IV (%)*  *OR*^b^      *95% CI*    P*-value adj*^b^
  ------------------ ----------------------------- ---------------------------- -------------- ------------- -------------------------------------- ----------------------------------- --------- -------------- ------------------
  *Stage*                                                                                                                                                                                                        
  1p−                RP11-219F4 (36.2--36.3)       1p36.2-36.3                    14 774.025    14 774 291   0.002                                                 17/29                2.16       (1.26--3.72)  0.005
                                                                                                                                                                                                                  
  2p+                RP11-57F9                     2p23                           28 514.930    28 515 223   0.0056                                                13/23                1.89       (1.06--3.38)  0.03
  2q+                CTD-22500B20 (2q22)           2q22-24.3                     158 357.236    158 357 713  0.0034                                                9/20                 2.94       (1.52--5.71)  0.001
  3q+                RP11-160A13 (3q23-24)         22-24, 26-29, tel             144 154.808    144 312 333  0.0015                                                12/25                1.74       (0.97--3.11)  0.06
  4p−                RP11-126C7 (4p13)             11-12,13                       38 087.290     38 242.92   0.0066                                                12/26                2.24       (1.32--3.41)  0.03
  4q−                RP11-101N17 (4q26)            4q11-12, 26                   120 563.175    120 720 926  0.0003                                                14/29                2.42       (1.35--4.43)  0.003
  6p−                RP11-284E1 (6p12)             6p12, 24-25                    53 823.776    53 824 135   0.0003                                                14/30                2.48       (1.37--4.42)  0.001
                                                                                                                                                                                                                  
  7q+                RP11-38P11 (7q32)             7q26.2-.3, 32,34,36.3         129 557.600    129 557 976  0.0018                                                26/41                1.63       (1.02--2.63)  0.04
                                                                                                                                                                                                                  
  9p−                RP11-125K10 (9p24)            9p21-24, tel                    4819.655      4 991 841   8.63E-0.05                                            28/49                2.17       (1.33--3.53)  0.002
  9q−                RP11-8D10 (9q21.3)            9q12-21.3                      82 120.447    82 209 078   8.63E-0.05                                            28/46                2.28       (1.41--3.70)  0.001
  12p+               RP11-78F16 (12p11.2)          12p11.2,12.1-13.1              31 959.002    32 128 568   0.0005                                                20/32                2.04       (1.20--3.45)  0.008
  12q+               RP11-89E9 (12q23)             12q23.3                        97 222.144    97 411 481   0.0005                                                18/31                2.14       (1.26--3.64)  0.005
  13q−               RP11-8C15 (13q12.1)           13q12.1,12.3-14.3,21.1-tel     20 985.475    20 993 099   8.63E-0.05                                            15/38                3.72       (2.11--6.57)  \<0.00001
  14q−               RP11-206J4 (14q23)            14q13-24, 31-32, tel           63 996.230    64 080 508   0.0003                                                38/62                2.36       (1.48--3.75)  \<0.00001
  16p−               CTD-2032H1                    16p13                           3232.028      3 296 628   0.0104                                                14/28                2.01       (1.28--3.33)  0.01
  17q+               RP11-86L18                    17q12-25.3,36                 153 645.400    153 645 775  0.0003                                                27/43                1.63       (1.02--2.60)  0.04
  18p−               RP11-106J7 (18p11.21-.23)     18p11.2-12                      3268.728      3 443 000   0.0002                                                13/35                3.15       (1.81--5.48)  \<0.00001
  18q−               RP11-12J12 (18q22)            18q11-12, 21-23, tel           55 424.497    55 607 583   3.14E-0.06                                            27/43                2.84       (1.68--4.88)  \<0.00001
  20q+               LLNL-255K9                    20q13.2                        55 338.240    55 352 455   0.0005                                                15/34                2.24       (1.31--3.82)  0.003

Abbreviations: ccRCC, clear cell renal cell carcinoma; CI, confidence interval; OR, odds Ratio.

*P*-value adjusted for multiple comparisons.

OR, 95% CI and *P*-values from multivariate models(MV) adjusted for age, sex, country stage, grade, smoking status and family history of cancer.

###### Regional clone and copy number alterations and patient/tumor characteristics

  *Sex*                                  *Clone with highest signal*   *Region altered*    *Start (Mb)*              *End*            P*-value adj*[a](#t3-fn1){ref-type="fn"}    *Male (*%*)/female (*%)  *OR (MV)*[b](#t3-fn2){ref-type="fn"}[c](#t3-fn3){ref-type="fn"}    *95% CI*[b](#t3-fn2){ref-type="fn"}  P*-value*[b](#t3-fn2){ref-type="fn"}
  -------------------------------------- ----------------------------- ------------------- -------------- --------------------------- ------------------------------------------ ------------------------- ----------------------------------------------------------------- ------------------------------------- --------------------------------------
  1q+                                    RP11-188A4 (1q43-44)          1q43-44             239 316.500             2.39E+08           0.002                                           **[17]{.ul}**/9      2.56                                                                          (1.43--4.55)              0.04
  6p−                                    RP11-52C20 (6p22)             6p22, 24-25         23 943.950             24 112 567          0.01                                           **[22]{.ul}**/11      2.22                                                                          (1.18--4.17)              0.003
  9q−                                    RP11-19014 (9q13)             9q13, 21.1-22, 33   70 455.470             70 634 947          0.003                                          **[38]{.ul}**/21      2.13                                                                          (1.30--3.57)              0.001
  12p+                                   RP11-174L5(12p12.3)           12p12.3             14 735.670             14 736 047          0.001                                          **[38]{.ul}**/19      2.44                                                                          (1.45--4.00)              0.001
  12q+                                   RP11-29G23 (12q12.4)          12q12.4, 24-tel     43 908.780             43 909 199          0.02                                           **[25]{.ul}**/14      1.92                                                                          (1.11--3.33)              0.004
                                                                                                                                                                                                                                                                                                                   
  *Family history*                                                                                                                    No (%)/yes (%)                                                                                                                                                               
   4q−                                   RP11-7G22 (4q21.3-22)         4q21-23             84 523.610             84 723 458          0.002                                          **[24]{.ul}**/11      2.70                                                                          (1.45--5.26)              0.002
   20q+                                  RP11-15M15 (20q13.2)          20q13.2             51 109.650             51 266 870          0.003                                          **[26]{.ul}**/13      2.38                                                                          (1.41--4.55)              0.002
                                                                                                                                                                                                                                                                                                                   
  *Ever smoker*                                                                                                                       Never (%)/ever (%)                                                                                                                                                           
   16p+                                  RP11-150K5 (16p11.2)          16p11.2-13.2        29 825.190             29 825 404          0.003                                          11/**[22]{.ul}**      2.72                                                                          (1.42--5.21)              0.003
   3q−                                   CTD-2014B13 (3q13.2)          3q12-14             100 971.500             1.01E+08           0.03                                           24/**[40]{.ul}**      1.73                                                                          (1.06--2.83)              0.04
                                                                                                                                                                                                                                                                                                                   
  *Von Hippel--Lindau gene alteration*                                                                     Wild-type (%)/altered (%)                                                                                                                                                                               
   3p−                                   RP11-180G14 (3p14.3)          3p14.3              59 538.560             59 538 883          0.02                                           71/**[92]{.ul}**      4.88                                                                          (2.23--10.68)             \<0.00001
                                         RP11-245E5 (3p24)             3p21-25, tel        22 747.910             22 936 416          1.97E-07                                       63/**[95]{.ul}**      13.48                                                                         (6.01--30.20)             \<0.00001
   20q+                                  LLNL-255K9 (20q13.2)          20q11-13.2          55 338.240             55 352 455          0.03                                           **[33]{.ul}**/20      2.08                                                                          (1.04--4.17)              0.03

Abbreviations: CI, confidence interval; MV, multivariate model; OR, Odds Ratio.

*P*-value adjusted for multiple comparisons.

OR, 95% CI and *P*-values from MV adjusted for age, sex, country stage, grade, smoking status and family history of cancer.

ORs presented for most prevalent comparison group (underlined).

###### List of published comparative genomic hybridization (CGH) studies of kidney and renal cell carcinoma (RCC)

  *Manuscript*                                                       *Sporadic ccRCC Cases*   *Other tissues evalauted*       *Method*                  *Factors evaluated*                                                           Finding
  ----------------------------------------------------------------- ------------------------- ------------------------------- ------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wilhelm *et al.*^[@bib22]^                                                   16             13 Papillary, 5 chromophobe,    Array CGH-329 clones      RCC subtype segregation                                                       Segregation of kidney tumor histological sub-types by copy number variation (CNV) differences
                                                                                              6 Oncocytoma, 2 normal kidney                                                                                                           ccRCC 3p−, 5q+, and 6q−, 8p−, 9p− or 14q−
  Toma *et al.*^[@bib17]^                                                      22             22 Matched normal tissue        Affymetrix 10k chip       Survival                                                                      CNV most frequent at 3p−, 5q+, 14q−, 9−,7q+, 6q−
                                                                                                                                                        qPCR, immunohistochemistry (IHC)                                              Novel microdeletions at Chr1 , Chr 4, Chr6, Chr8 and Chr 9
                                                                                                                                                                                                                                      Some alterations validated using gene and immunohistochemical (IHC) protein expression assays
  Arai *et al.*^[@bib18]^                                                      51             NA                              array CGH (4361 BACs)     Survival, grade, stage, vascular InvolvementPromoter methylation in 9 genes   CNV most frequent at 3p−, 5q+, 7+Genetic cluster profiles associated with survivial, independent of grade, stage
  Chen *et al.*^[@bib20]^                                                      80             NA                              Illumina 317K SNP array   Stage, grade, telomere length                                                 CNV most frequent at 3p−, 5q+, 8p12-pter, 6q23.3-27, 14q24.1-qter, 9q32-qter,
                                                                                                                                                        Demographics, smoking, alcohol, medical Hx                                    10q22.3-qter, 9p13.3-pter, 4q28.3-qter, 1q25.1-qter, 7q21.13-qter, 8q24.12-qterLoss of heterozygosity (LOH) 9p, 9q, 14q, 18q associated with grade
                                                                                                                                                                                                                                      LOH 14q, 18p, 21q associated with stage
                                                                                                                                                                                                                                      LOH 2q, 6p, 6q, 9p, 9q, 17p associated with short telomere length
  Beroukhim *et al.*^[@bib19]^                                          49, 5 Metastases      36 Tumors/12 VHL patients       Affymetrix 250K StyI      Von Hippel--Lindau (VHL) disease, *VHL* inactivation, grade,                  CNV most frequent at 3p−, 14q−, 5q+CNV higher in VHL WT compared with VHL disease cases
                                                                                                                                                        Gene expression differences                                                   LOH 1p, 3p (VHL), 4q, 6q, 8p, 9p (CDKN2A, 2B) and 14q
                                                                                                                                                                                                                                      Amplification 1q, 2q, 5q, 7q, 8q (MYC), 12p and 20q
  Shuib *et al.*^[@bib21]^ (data combined with Beroukim *et al.*)    22 *VHL* wild-type (WT)  57 VHL patients                 Affymetrix 250K           VHL disease (germline)                                                        CNV most frequent at 3p−, 14q−, 5q+7p+, 8p− (TNFRSF10C, DUSP4) associated with germline *VHL* clear cell RCC17p− (TP53), 2p+ (HIF2A) associated with VHL wild-type ccRCC
  Moore *et al.*, current study                                        412 Clear cell RCC                                     Array CGH (2464 BACs)     *VHL* inactivation, age, sex, stage, grade                                    CN loss most frequent at 3p, 14q, 8p, 4q, 9p, 9q, 6q, 3q, 10q, 13q, 1q,
                                                                                                                                                        Body mass index, hypertension, family cancer Hx,                              CN gain at 5q, 7q, 7p, 5p, 20q, 12q, 12pStage and grade associated with 1p−, 9p−, 9q− 13q−, 14q−, 12q+
                                                                                                                                                        Occupational solvent, lead, pesticide, exposures                              CNV higher among *VHL* wild-type compared to hypermethylated casesLOH across 3p varied by *VHL* inactivation status
                                                                                                                                                        *LINE1* methylation                                                           CNV higher in male compared to females cases, independent of grade, stage
                                                                                                                                                                                                                                      CNV higher in cases without positive family Hx cancer
                                                                                                                                                                                                                                      Smoking associated with 16p11.2-13.2 gain

Abbreviations: ccRCC, clear cell renal cell carcinoma; CGH, array comparative genomic hybridization; NA, not applicable.
